Ananda M Chakrabarty
Overview
Explore the profile of Ananda M Chakrabarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi J, Naffouje S, Goto M, Wang J, Christov K, Rademacher D, et al.
Commun Biol
. 2023 Jan;
6(1):16.
PMID: 36609683
Microorganisms living at many sites in the human body compose a complex and dynamic community. Accumulating evidence suggests a significant role for microorganisms in cancer, and therapies that incorporate bacteria...
2.
3.
Hashimoto W, Ochiai A, Hong C, Murata K, Chakrabarty A
Bioengineered
. 2015 Feb;
6(3):141-8.
PMID: 25714335
Azurin and Laz (lipidated azurin) are 2 bacterial proteins with anticancer, anti-viral and anti-parasitic activities. Azurin, isolated from the bacterium Pseudomonas aeruginosa, termed Paz, demonstrates anticancer activity against a range...
4.
Chakrabarty A, Bernardes N, Fialho A
Bioengineered
. 2014 May;
5(4):234-42.
PMID: 24875003
Cancer is one of the most deadly diseases worldwide. In the last three decades many efforts have been made focused on understanding how cancer grows and responds to drugs. The...
5.
Chakrabarty A
Adv Exp Med Biol
. 2014 Mar;
808:41-9.
PMID: 24595609
Pathogenic microorganisms, particularly pathogenic bacteria that cause debilitating diseases, are considered a threat for human health and well-being. Infectious diseases are rampant, particularly in developing countries. However, there are many...
6.
Xu P, Yu H, Chakrabarty A, Xun L
Genome Announc
. 2013 Aug;
1(4).
PMID: 23929488
Burkholderia phenoliruptrix strain AC1100 (ATCC 53867) degrades a variety of recalcitrant xenobiotics, including 2,4,5-trichlorophenoxyacetate. The molecular mechanism of 2,4,5-trichlorophenoxyacetate degradation has been extensively studied. Here we present a 7.8-Mb assembly...
7.
Bernardes N, Chakrabarty A, Fialho A
Appl Microbiol Biotechnol
. 2013 May;
97(12):5189-99.
PMID: 23644748
The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and...
8.
Fialho A, Chakrabarty A
Cancer Biol Ther
. 2012 Sep;
13(13):1229-34.
PMID: 22954683
Patents are issued essentially by all countries on inventions that are deemed novel, non-obvious, clearly described and of significant utility or industrial application. The only exceptions to patenting an invention...
9.
Avner B, Fialho A, Chakrabarty A
Bioengineered
. 2012 Jul;
3(5):262-70.
PMID: 22750915
Resistance development against multiple drugs is a common feature among many pathogens--including bacteria such as Pseudomonas aeruginosa, viruses, and parasites--and also among cancers. The reasons are two-fold. Most commonly-used rationally-designed...
10.
Fialho A, Salunkhe P, Manna S, Mahali S, Chakrabarty A
ISRN Neurol
. 2012 Mar;
2012:642345.
PMID: 22462021
The current therapy for glioblastoma multiforme involves total surgical resection followed by combination of radiation therapy and temozolomide. Unfortunately, the efficacy for such current therapy is limited, and newer approaches...